ArticleMaterials (Basel, Switzerland)2021
An In Vitro-In Vivo Simulation Approach for the Prediction of Bioequivalence.
Article in Materials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Pilot study: bioequivalence of dihydroartemisinin in dihydroartemisinin-piperaquine tablet generic formulation in healthy Indonesian volunteers.Nagoya journal of medical science · 2023Trial
- Comparison of Metrics for Investigating Bioequivalence in Onset of Action in Incurred Bioequivalence Studies.Pharmaceutics · 2026Article
- Development of a pH Gradient Dissolution Condition to Predict the Behavior of Delayed Release Formulations under Fed In Vivo Condition.AAPS PharmSciTech · 2025Article
- Fluoride Casein Phosphopeptide and Tri-Calcium Phosphate Treatments for Enamel Remineralization: Effects on Surface Properties and Biofilm Resistance.Dentistry journal · 2025Article
- Modeling and comparison of dissolution profiles for different brands of albendazole boluses.BMC pharmacology & toxicology · 2024Article
- A Vector Theory of Assessing Clinical Trials: An Application to Bioequivalence.Journal of cardiovascular development and disease · 2024Article
- Potential Surviving Effect ofAntibiotics (Basel, Switzerland) · 2024Article
- An In Silico Approach toward the Appropriate Absorption Rate Metric in Bioequivalence.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Design of Oral Sustained-Release Pellets by Modeling and Simulation Approach to Improve Compliance for Repurposing Sobrerol.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The aim of this study was to develop a new in vitro-in vivo simulation (IVIVS) approach in order to predict the outcome of a bioequivalence study. The predictability of the IVIVS procedure was evaluated through its application in the development process of a new generic product of amlodipine/irbesartan/hydrochlorothiazide. The developed IVIVS methodology is composed of three parts: (a) mathematical description of in vitro dissolution profiles, (b) mathematical description of in vivo kinetics, and (c) development of joint in vitro-in vivo simulations. The entire programming was done in MATLAB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.